Dupilumab effectively treated nasal polyposis with minimal toxicity among treatment-refractory patients in a real-world setting, according to results of a retrospective cohort study published in ...

Juvenile polyposis syndrome with outlet obstruction of the stomach and excessive hypergastrinemia. Management. Continuous acid-suppressive therapy, prokinetic therapy and total parenteral nutrition.

Juvenile polyposis syndrome, also known as familial juvenile polyposis, is a hereditary genetic syndrome. It is usually transmitted in an autosomal dominant fashion, but may be due to a new ...

Global nasal polyposis treatment market to expand nearly 2x from 2023 to 2033 Corticosteroids account for 55% of all nasal polyposis treatment types, expanding at a 9% CAGR More than 3 out of 5 nasal ...

Patients with germline pathogenic variants (PVs) in APC develop tens (attenuated familial adenomatous polyposis [AFAP]) to innumerable (classic FAP) adenomatous polyps in their colon and are at ...

Therapyx Inc.’s Fapxil has been awarded orphan drug designation by the FDA for the treatment of familial adenomatous polyposis (FAP).

Background A 64-year-old woman presented to the emergency room with a 3-month history of intermittent abdominal cramps, accompanied by nausea, vomiting, anorexia, and decreased bowel movements ...

Biodexa Pharmaceuticals, a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the activation of the ...

Diagnosis: Familial adenomatous polyposis with mental retardation, caused by an interstitial deletion of the long arm of chromosome 5 encompassing the APC (adenomatous polyposis coli) tumor ...

Biodexa Pharmaceuticals announces "Serenta" as the name for its Phase 3 study in Familial Adenomatous Polyposis, launching a dedicated website. Biodexa Pharmaceuticals PLC has announced "Serenta ...